NNMT inhibitor
5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor with results in cells, mice and rats; a ClinicalTrials.gov search under three spellings of its name on 16 November 2026 returned 0 studies.
5-Amino-1MQ after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.
Drawn from the half-life in the app's model, ~6 h. The model's figures
- Compound
- 5-Amino-1MQ
- Symbol
- 5AM
- Family
- Metabolic and mitochondrial peptides
- Parts
- 15
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

2%The 25th most tracked compound in Milligram: of people who track compounds in Milligram logged 5-Amino-1MQ in the last 90 days.
Schedule
Logged doses
Half of people logged between 2.5 and 5 mg per dose; the median was 5 mg.
Tracked alongside
The share of people logging 5-Amino-1MQ who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT).1,2 Harshini Neelakantan, Stanley Watowich and colleagues at the University of Texas Medical Branch in Galveston and the University of Texas at San Antonio reported the quinolinium inhibitor series in the Journal of Medicinal Chemistry in 2017, with NNMT inhibition at an IC50 of about 1 µM for the scaffold.3 Its in vivo results come from mice and its pharmacokinetics from rats and mice.4,5 Other groups have used it in cell and mouse cancer experiments.6,11,13
A search of PubMed on 16 November 2026 for 5-amino-1MQ, 5A1MQ, 5-amino-1-methylquinolinium or 5-AMQ returned 6 records, and none describes giving the compound to people. A search of ClinicalTrials.gov on 16 November 2026 for 5-amino-1MQ, 5-amino-1-methylquinolinium and 5A1MQ returned 0 studies. A 2026 review of NNMT inhibitors by Puleo and colleagues at the University of Chicago, in Trends in Pharmacological Sciences, states, of NNMT small-molecule inhibitors as a class, that "insufficient target engagement, reduced bioavailability, and unknown safety profiles have led to limited preclinical success across diseases", and that newer compounds are "drug-like compounds with high affinities for cellular NNMT and promising safety profiles".7
Four of the group's papers from 2021 onward declare ties to a company, Ridgeline Therapeutics: Sampson and colleagues, 2021, Dimet-Wiley and colleagues, 2022 and 2024, and Babula and colleagues, 2024.2,8,9,5 Dimet-Wiley and colleagues, 2024, state that "SJ Watowich is the Founder of Ridgeline Therapeutics; AL Dimet-Wiley and H Neelakantan are employees of Ridgeline Therapeutics".9 Awosemo and colleagues, 2021, the source of the rat figures, share two authors with that group (Neelakantan and Watowich), list an NIA grant (R21 AG063056) and state "The authors report no declarations of interest".4 The 2018 and 2019 papers by Neelakantan and colleagues each state "The authors declare no conflict of interest".1,10
How it works
Sources in this part
The enzyme
Neelakantan and colleagues write that "NNMT is a cytosolic enzyme with a newly identified role in modulating cellular energy homeostasis" by jointly regulating nicotinamide and S-adenosyl-L-methionine (SAM) flux.1 They note, citing earlier work, that plasma levels of its reaction product, 1-methylnicotinamide (1-MNA), "correlate with adipose NNMT expression", body mass index and waist circumference.1 Sampson and colleagues state that NNMT messenger RNA expression is increased in both the omental and subcutaneous adipose tissues of individuals with type 2 diabetes.2
In cells
In differentiated 3T3-L1 adipocytes, 5-amino-1MQ reduced intracellular 1-MNA with a calculated EC50 of 2.3 +/− 1.1 µM, and at 10 to 60 µM the relative 1-MNA level stabilized at about 40% of untreated adipocytes.1 Intracellular NAD+ rose about 1.2 to 1.6-fold at 1 to 60 µM, although the overall test across treatments gave P = 0.0568, with a significant increase at 10 µM (P < 0.05); SAM rose significantly at 30 µM, and nicotinamide and S-adenosyl-L-homocysteine showed no significant main effect.1 Lipid accumulation in differentiating 3T3-L1 cells fell by 50% at 30 µM and 70% at 60 µM.1
In mice
In Babula and colleagues, mice given 25 mg/kg subcutaneously for 5 days had 1-MNA levels in epididymal fat and muscle that the authors describe as "suggesting nearly 70% and 40% inhibition of 1-MNA at 1 h post-dose", relative to the levels at 8 hours after dosing, and the 32 mg/kg/day group showed a mean 39% lower liver 1-MNA than controls at the end of the study.5
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 h
- Bioavailability
- 95%
- Typical dose
- 50–100 mg
- Route
- Oral
- Time to peak
- ~1 h
The figures row above is the app's, not taken from the studies: the app lists a half-life of about 6 hours, oral bioavailability of 95%, a time to peak of about 1 hour and an oral route. The sources contain measurements from rats and mice, and none of the 6 PubMed records returned on 16 November 2026 describes a measurement in people. The rat and mouse figures differ from the app's figures and from each other, with oral bioavailability of 38.4% in rats and 3.5% in mice against the app's 95%.
| Parameter | Value | Reported in the sources |
|---|---|---|
| Half-life | ~6 h (the app's figure) | Rats, terminal elimination half-life 6.90 ± 1.20 h after an oral dose and 3.80 ± 1.10 h after an intravenous dose (n and doses not stated in the PubMed record).4 Mice, 6.3 h after 5 mg/kg intravenously (n = 3), 13.3 h and 12.8 h after a single (n = 6) and repeated (n = 12) 25 mg/kg subcutaneous dose, and an estimated 14.8 h after 30 mg/kg orally (n = 3).5 Mice, subcutaneous, "a robust half-life (~ 7 h)".9 |
| Oral bioavailability | 95% (the app's figure) | Rats, "a good oral bioavailability (F % = 38.4)" (n and dose not stated in the PubMed record).4 Mice, 3.5% after 30 mg/kg orally (n = 3), which the authors attribute as "likely" to limited enteric absorption and high first-pass metabolism.5 Dimet-Wiley and colleagues state that the compound "has poor oral bioavailability in mice, a phenomenon that does not occur in rats".8 |
| Time to peak | ~1 h (the app's figure) | Mice, about 15 minutes after a 25 mg/kg subcutaneous dose (n = 6) and 4 h after a 30 mg/kg oral dose (n = 3).5 |
| Peak concentration | Not an app figure | Rats, a mean maximum plasma concentration of 2252 ng/mL after oral administration (dose and n not stated in the PubMed record).4 Mice, 14.5 ng/mL after 30 mg/kg orally (n = 3), 7,010 ng/mL after a single 25 mg/kg subcutaneous dose (n = 6) and 2,009 ng/mL after 5 mg/kg intravenously (n = 3).5 |
| Membrane permeability in cell assays | Not an app figure | In a Caco-2 cell assay the apical-to-basolateral permeability of 5-amino-1MQ was 34.2 and the basolateral-to-apical 45.2 (10−6 cm/s), an efflux ratio of 1.33, classed as high permeability with no efflux; the authors say these results suggest "high oral absorption and bioavailability for these compounds".1 |
| Route | Oral (the app's figure) | The mouse efficacy studies that state a route gave the compound by subcutaneous injection (Sampson and colleagues, 2021, state none); Dimet-Wiley and colleagues state that subcutaneous injection "was chosen as 5A-1MQ specifically has poor oral bioavailability in mice".8 |
In mice given 25 mg/kg subcutaneously for 5 days, the epididymal fat-to-plasma concentration ratio rose from 1.4 at 1 hour to 31.1 at 8 hours, and the muscle-to-plasma ratio from 2.2 to 17.0 (n = 3 mice per timepoint).5 Dimet-Wiley and colleagues report "an absence of accumulation with repeat dosing" after subcutaneous dosing in mice.9
Human studies
A search of PubMed on 16 November 2026 for 5-amino-1MQ, 5A1MQ, 5-amino-1-methylquinolinium or 5-AMQ returned 6 records, and none describes giving the compound to people. Three of the 6 are rat or mouse papers (Awosemo 2021, Dimet-Wiley 2022, Babula 2024) and three are cancer cell or cancer-model papers (Pompei 2025, Yang 2024, Akar 2021).4,8,5,13,6,11 The search is not complete: it did not return five papers cited here (Neelakantan and colleagues, 2017, 2018 and 2019, Sampson and colleagues, 2021, and Dimet-Wiley and colleagues, 2024), several of which write the name differently, as "5-amino-1-methylquinolium" or "5A-1MQ".3,1,10,2,9 Yang and colleagues, Journal for ImmunoTherapy of Cancer, 2024, examined NNMT expression in samples from people with urothelial bladder cancer, and reported tumor growth results for the inhibitor in mouse models.6 A search of ClinicalTrials.gov on 16 November 2026 for 5-amino-1MQ, 5-amino-1-methylquinolinium and 5A1MQ returned 0 studies; searches of the same registry for NNMT and for nicotinamide N-methyltransferase returned 3 studies in total, none listing the compound. A web search the same day for a human pharmacokinetic or safety study of 5-amino-1MQ returned no peer-reviewed study.
Animal and cell studies
The studies below are in mice, rats and cultured cells, and the results are not results in people.
| Study and year | Design | Animals | Dose and length | Main result |
|---|---|---|---|---|
| Neelakantan and colleagues, 20181 | Randomised, vehicle-controlled, 11 days | Male diet-induced obese mice, n = 9 per cohort | 20 mg/kg per injection subcutaneously, three times a day, 11 days | Body weight fell 2.0 ± 0.6 g (about 5.1%) against a gain of 0.6 ± 0.4 g (about 1.4%) in controls; epididymal fat mass about 35% lower (P < 0.001); adipocyte size more than 30% lower (P < 0.05); total cholesterol about 30% lower (P < 0.05); cumulative food intake 26.2 ± 1.4 g against 28.1 ± 1.2 g (not significant). |
| Neelakantan and colleagues, 201910 | Randomised saline, 5 or 10 mg/kg groups; barium chloride injury to one leg muscle | 24-month-old mice, n = 13, 10 and 13 per group; separate cohort n = 6 per group | 5 or 10 mg/kg subcutaneously twice a day for 2 weeks; 10 mg/kg for 4 weeks in the second cohort | At 10 mg/kg the mean fibre cross-sectional area of the injured muscle was 1.8-fold that of controls with 1 week of post-injury dosing (p = 0.0052) and 1.5-fold with 3 weeks (p = 0.039), while 5 mg/kg did not significantly alter it (p > 0.05); peak torque per body weight was 67% higher in the treated group than in controls (p = 0.033); torque per fibre area did not differ; one mouse with unusually low area was excluded from the 3-week analysis. |
| Sampson and colleagues, 20212 | Randomised; lean-diet switch with or without the compound; lean and Western-diet controls | Diet-induced obese mice, n = 6 to 8 per group | 4 mg/mL at 10 µL per gram body weight, daily, to study day 47 to 49 (route not stated in the paper) | Cumulative body weight loss 6.3 g at study end with the compound and a lean diet, against 2.9 g by day 45 with the lean diet alone (different timepoints); fat mass loss about 29.3% against 2.9%; food intake did not differ significantly by treatment group. |
| Dimet-Wiley and colleagues, 20249 | Randomised, 2 by 2: sedentary or weighted wheel running, saline or compound | 22-month-old female mice, n = 35 (9, 9, 10 and 7 per group) | 10 mg/kg body weight, daily subcutaneous injection for eight weeks, from 22 to 24 months of age | At week 6, treated sedentary mice had about 40% greater grip strength than sedentary controls, and the exercised groups about 20% and 60% (the paper's summary and its results text assign these two figures to different groups); normalised to body weight, treated sedentary against sedentary gave P < 0.06. Mice assigned to treatment were roughly 10% heavier at the start, sedentary mice were group-housed and exercised mice singly housed, and peak torque did not correlate with grip strength in any group. |
| Babula and colleagues, 20245 | Randomised, saline-controlled, once daily; the paper gives 28 days in one place and 30 days in another | Diet-induced obese mice, n = 8 per group | 10 or 32 mg/kg/day subcutaneously | At 32 mg/kg/day weight gain was 0.9 g against 5.4 g (control) and 5.2 g (10 mg/kg/day); fat mass gain 1.3 g against 4.7 g; no significant effect on food intake or lean mass. |
| Awosemo and colleagues, 20214 | Pharmacokinetic study with an LC-MS/MS method | Rats | Intravenous and oral doses (amounts not stated in the PubMed record) | Mean terminal elimination half-life 3.80 ± 1.10 h intravenously and 6.90 ± 1.20 h orally; oral bioavailability 38.4%. |
Other groups have used the compound in cancer cell experiments. Akar and colleagues, Journal of Obstetrics and Gynaecology, 2021, tested 0.1 to 500 µM of a compound the paper writes as "5MQ" (first expanded as "5-methylquinolinium", later as 5-amino-1-methylquinolinium) on the HeLa cervical cancer cell line and report that it "significantly inhibited HeLa cell proliferation in a concentration and time-dependent manner", without apparently affecting HEK-293 cell proliferation.11 Pompei and colleagues, Biomolecules, 2025, report that 5-AMQ and two other NNMT inhibitors gave "significant reductions in viability" in osteosarcoma and Merkel cell carcinoma cell lines.13
Deeper analysis: Neelakantan and colleagues, 2018
Design: Neelakantan and colleagues at the University of Texas Medical Branch (Galveston) and the University of Texas at San Antonio, writing in Biochemical Pharmacology, ran an 11-day proof-of-concept study in male diet-induced obese mice, after a cell programme of permeability, viability and selectivity tests.1 The paper gives 20 mg/kg per injection three times a day, a total of about 34 mg/kg/day of the parent compound.1
The authors report that triglyceride values "were not included for analysis since the measurements were confounded by sample hemolysis".1 The dose was chosen from "an initial dose escalation study (ranging from 10 mg/kg/day to a total dose of 150 mg/kg/day) in DIO mice (n=2)", in which 60 mg/kg/day was well tolerated.1 Funding came from a US Department of Defense Peer Reviewed Medical Research Program grant (PR141776), a University of Texas Medical Branch Technology Commercialization Award and an NIH grant (R01GM112936).1
Deeper analysis: Babula and colleagues, 2024
Design: Babula and colleagues, of Ridgeline Therapeutics (Houston) and the University of Texas Medical Branch, report in Diabetes, Obesity and Metabolism a 30-day once-daily subcutaneous study at 10 or 32 mg/kg/day in diet-induced obese mice (n = 8 per group) and a separate pharmacokinetic study.5 Found: plasma insulin rose 112% from day 0 to day 28 in controls and 46% at the low dose, and fell 9% at the high dose; liver weight averaged 2.1 g in controls and 1.4 g at the high dose; microvesicular steatosis was 73% lower than in controls.5
Also found: total white blood cell count was lower at the high dose, driven by a 31% decrease in lymphocytes and a 50% decrease in monocytes against controls, and creatine kinase and lactate dehydrogenase were significantly lower at the low dose and not at the high dose.5 Limitations stated by the authors: "Ongoing efforts are addressing further optimization of 5A1MQ, including improving species (e.g., mouse)-specific high metabolic clearance and off-target activity against MAO-A".5 Funding and ties: in vivo studies were run by Wuxi Apptec Ltd., the grants were from the NCATS (KL2TR001441-06), NIDDK (1R41DK119052-01) and the Department of Defense (PR180216), and the competing interests state that SJW founded Ridgeline Therapeutics, HN is a paid employee, and JJB and DB are former employees.5
Doses reported in studies
The doses below are those given to animals, in the units each paper gives (mostly mg per kg of body weight), and the PubMed records returned describe no dose given to people. The dose basis is stated for two rows only: the parent compound by free weight (Neelakantan and colleagues, 2018) and the active ingredient of a monochloride salt (Dimet-Wiley and colleagues, 2022).1,8
| Source | Dose and route | Frequency | Length |
|---|---|---|---|
| Neelakantan and colleagues, 20181 | 20 mg/kg per injection subcutaneously, mice (the paper gives about 34 mg/kg/day of the parent compound in total) | Three times a day | 11 days |
| Neelakantan and colleagues, 2018, dose escalation1 | 10 to 150 mg/kg/day, mice (n = 2) | Not stated | Not stated |
| Neelakantan and colleagues, 201910 | 5 or 10 mg/kg subcutaneously, aged mice | Twice daily | 2 weeks; 4 weeks at 10 mg/kg |
| Sampson and colleagues, 20212 | 4 mg/mL at 10 µL per gram body weight, mice (route and dose basis not stated in the paper) | Daily | To study day 47 to 49 |
| Dimet-Wiley and colleagues, 20228 | 32 mg/kg of active ingredient subcutaneously, mice | Daily | About 7 weeks |
| Dimet-Wiley and colleagues, 20249 | 10 mg/kg body weight subcutaneously, aged female mice | Daily | Eight weeks, from 22 to 24 months of age |
| Babula and colleagues, 20245 | 10 or 32 mg/kg/day subcutaneously, mice | Once daily | 30 days |
| Babula and colleagues, 2024, pharmacokinetics5 | 5 mg/kg intravenously, 30 mg/kg orally, 25 mg/kg subcutaneously, mice | Single dose; once daily for 5 days at 25 mg/kg subcutaneously | Single dose; 5 days |
The app lists a typical dose of 50 to 100 mg; the sources report no dose in mg for people.
Side effects reported
No record returned by the search of PubMed on 16 November 2026 reports side effects in people, because none describes the compound given to people. In mice, in an 11-day study with 9 per cohort, Neelakantan and colleagues report that "administration of NNMT inhibitors did not impact total food intake nor produce any observable adverse effects", and the dose-escalation study behind that dose (n = 2) reports tolerability at a total of 60 mg/kg/day, with no result stated for higher doses.1 In the 2019 aged-mouse study, a plasma chemistry panel showed no significant differences between control and 10 mg/kg groups after the 1-week post-injury dosing period, and the authors state that the dosing "was well tolerated with no untoward systemic toxicity or behavioral implications".10 Sampson and colleagues write that repeated dosing over 7 weeks "did not produce any adverse effects and was well tolerated", with serum chemistry markers not significantly different between groups except total protein and albumin, which were higher in the vehicle-treated group switched to a lean diet.2
In Babula and colleagues, total white blood cell count was lower at the high dose than in controls, with a 31% decrease in lymphocytes and a 50% decrease in monocytes, and monocytes were also lower at the low dose (p < 0.01); the authors write that treatment "greatly reduced white blood cell levels through large decreases in lymphocytes and monocytes, which aligned with improved insulin sensitivity".5 In cultured 3T3-L1 cells, concentrations of 100 to 300 µM gave modest cytotoxicity and 600 µM about 40%.1 The 2026 review by Puleo and colleagues states, of NNMT small-molecule inhibitors as a class and not of 5-Amino-1MQ in particular, that "unknown safety profiles" are among the factors that "have led to limited preclinical success across diseases", and that newer compounds have "promising safety profiles".7
Bloodwork and markers
Sources in this part
In mice, Babula and colleagues report that the high dose lowered fed-state plasma insulin, glucose at 15 and 30 minutes of a glucose tolerance test, serum triglycerides, alanine transaminase and ketone bodies against controls.5 Neelakantan and colleagues, 2018, report total plasma cholesterol about 30% lower in treated mice and excluded triglycerides because of sample hemolysis.1 The sources report no blood glucose, HbA1c or body weight measure in people given the compound.
Regulatory and anti-doping status
Sources in this part
The WADA 2026 Prohibited List does not name 5-Amino-1MQ in its text. Section S0 reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times".12 The list text does not state whether S0 applies to 5-Amino-1MQ.12 A web search on 16 November 2026 for FDA, WADA and TGA documents on 5-amino-1MQ returned vendor and information sites, and no document from those bodies.
What is not known
The PubMed records returned on 16 November 2026 give no half-life, bioavailability, time to peak or dose in people, and the app's figures sit beside rat and mouse oral bioavailability of 38.4% and 3.5% and half-lives from 3.80 h to 14.8 h.4,5 Whether oral dosing in people reaches the exposure that subcutaneous injection reached in mice is not addressed by those records, which describe low systemic exposure with oral dosing in mice.5 Dosing in the studies listed here lasted from 11 days to 8 weeks, and from 22 to 24 months of age in one study, with 6 to 13 animals per group in the efficacy studies and 2 or 3 in the dose-escalation and pharmacokinetic groups.1,2,9,5 The body weight results in mice listed here come from one research group, four of whose papers from 2021 onward declare ties to Ridgeline Therapeutics (Awosemo and colleagues, 2021, declare none), and three of the 6 records returned by the search of PubMed are cancer cell or cancer-model studies.2
Frequently asked questions
What is 5-Amino-1MQ?
What is the half-life of 5-Amino-1MQ?
The app lists a half-life of about 6 hours, and the PubMed records returned on 16 November 2026 report none measured in people. Rats had a terminal elimination half-life of 6.90 ± 1.20 h after an oral dose and 3.80 ± 1.10 h after an intravenous dose (n and doses not stated in the PubMed record).4 Mice had 6.3 h after a 5 mg/kg intravenous dose (n = 3) and 13.3 h after a single 25 mg/kg subcutaneous dose (n = 6).5
Is 5-Amino-1MQ a peptide?
The papers describe 5-Amino-1MQ as a small molecule with a methylquinolinium scaffold, and not as a peptide.1
Has 5-Amino-1MQ been tested in humans?
A search of PubMed on 16 November 2026 under four spellings of its name returned 6 records, and none describes giving it to people. A search of ClinicalTrials.gov the same day under three spellings returned 0 studies.
What is the oral bioavailability of 5-Amino-1MQ?
What did 5-Amino-1MQ do in mice?
In one study in diet-induced obese mice given 20 mg/kg subcutaneously three times a day for 11 days, body weight fell about 5.1% from baseline against a gain of about 1.4% in controls.1
What are the side effects of 5-Amino-1MQ?
No record returned by the search of PubMed on 16 November 2026 reports side effects in people. In mice, Babula and colleagues report lower white blood cell counts at the high dose, which they describe as aligned with improved insulin sensitivity, while Neelakantan and colleagues, 2018, state that they saw no observable adverse effects, and the 2019 and 2021 studies state that dosing was well tolerated.5,1,10,2
Is 5-Amino-1MQ banned by WADA?
The WADA 2026 Prohibited List does not name 5-Amino-1MQ in its text. Section S0 prohibits at all times any pharmacological substance not addressed elsewhere on the list that has no current approval by a governmental regulatory health authority for human therapeutic use.12
What does an NNMT inhibitor do?
Neelakantan and colleagues report that NNMT inhibitors reduced intracellular 1-methylnicotinamide in cultured adipocytes, with a significant NAD+ increase at 10 µM (overall test P = 0.0568) and a significant SAM increase at 30 µM.1
Guides, tools and comparisons
References
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol 2018 (print year; online 2017). PMC5826726
- Sampson CM, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep 2021. PMC7952898
- Neelakantan H, et al. Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. J Med Chem 2017. PMID 28548833
- Awosemo O, et al. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal 2021. PMID 34304009
- Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab 2024. PMC11622326
- Yang M, et al. NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer 2024. PMID 39067875
- Puleo N, et al. Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation. Trends Pharmacol Sci 2026. PMID 42067476
- Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep 2022. PMC8748953
- Dimet-Wiley AL, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep 2024. PMC11226645
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol 2019. PMC6469996
- Akar S, et al. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells. J Obstet Gynaecol 2021. PMID 33645410
- World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
- Pompei V, et al. Small molecule inhibitors of nicotinamide N-methyltransferase enzyme for the treatment of osteosarcoma and Merkel cell carcinoma: potential for the development of a targeted therapeutic strategy. Biomolecules 2025. PMID 41301471